Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Shares in the NYSE-listed company dropped 2.8% at market open following the earnings, possibly a reflection of 2025 guidance.

(Reuters) -Johnson & Johnson said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates four reported stroke events. The ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ('Johnson & Johnson') (NYSE:JNJ) concerning ...

Johnson & Johnson has announced a temporarily pause in the rollout of its Varipulse heart device in the United States as it investigates four reported stroke events. The decision comes ...

On January 8, 2025, J&J issued a press release announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S.